https://doi.org/10.55788/40806c98
In the phase 3, placebo-controlled PACIFIC trial (NCT02125461), durvalumab after concurrent CRT significantly improved progression-free survival (PFS) and overall survival (OS) in patients with stage III, unresectable non-small cell lung cancer (NSCLC) [1]. This benefit was maintained in the recent 5-year update [2]. However, as many patients are ineligible for concurrent CRT, the phase 2 PACIFIC-6 trial (NCT03693300) aimed to assess safety with durvalumab after sequential CRT.
In PACIFIC-6, patients with ECOG performance status (PS) ≤2 and no progression after platinum-based sequential CRT were enrolled to receive durvalumab for 24 months or until progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was safety/tolerability of durvalumab, defined by the incidence of grade 3/4 possibly treatment-related adverse events occurring within 6 months of treatment initiation. PFS, OS, and overall response rate (ORR) were secondary endpoints. Dr Marina Garassino (University of Chicago, IL, USA) reported the primary safety analysis and secondary efficacy analyses from PACIFIC-6 [3].
A total of 117 patients were enrolled; 37.6% had stage IIIA, 50.4% had stage IIIB, and 11.1% had stage IIIC NSCLC. The median age was 68.0 years, 62.4% were male, and most patients had ECOG PS 0/1 (97.4%); 98.3% had past/present medical conditions, mostly vascular (59.0%), respiratory (53.8%), or metabolic (51.3%) disorders. All participants received ≥1 dose of durvalumab. The median duration of treatment was 32.0 weeks. At data cut-off, 37.6% were still on treatment, 29.9% discontinued due to progression, 21.4% discontinued due to adverse events, 8.5% discontinued due to other reasons, and 2.6% of patients had completed treatment.
Overall, 94.9% of participants had any adverse events and 76.9% had possible treatment-related adverse events. Grade 3/4 adverse events were observed in 18.8% of participants, and grade 3/4 possible treatment-related adverse events were observed in 4.3%. In 21.4% and 16.2%, adverse events and possible treatment-related adverse events led to discontinuation of treatment, respectively.
The median PFS was 10.9 months in the full cohort, and 13.1 months in the PS 0/1 cohort. Median OS was 25.0 months for the full cohort and in the PS 0/1 cohort; ORR was 17.1% and 17.5%, respectively. Best response to sequential CRT was complete response (n=1), partial response (n=75), and stable disease (n=32).
In summary, durvalumab after sequential CRT had a similar safety profile to that observed with durvalumab after concurrent CRT in the PACIFIC trial and showed encouraging preliminary efficacy in a frailer and older population.
- Antonia SJ, et al. N Engl J Med 2018; 379:2342–2350.
- Spigel DR, et al. J Clin Oncol. 2022;40(12):1301–1311.
- Garassino MC, et al. Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Abstract 108MO. ELCC 2022 Virtual Meeting, 30 March–02 April.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC Next Article
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC »
« No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC Next Article
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC »
Table of Contents: ELCC 2022
Featured articles
Early-Stage Non-Small Cell Lung Cancer
Real-world treatment and survival in early-stage NSCLC
Consistent efficacy of osimertinib in Chinese and global population
Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC
Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy
Advanced Non-Small Cell Lung Cancer
Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy
Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC
Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC
Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC
ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy
Savolitinib is effective in patients with MET-mutated NSCLC
Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC
Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Small Cell Lung Cancer
Total metabolic tumour volume: a new potential prognostic factor in SCLC
Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy
Characteristics of long-term survivors in the CASPIAN trial
Outcomes of real-world CANTABRICO trial match results from CASPIAN
Lung Cancer Epidemiology
Lung cancer diagnosis with liquid biopsy of peripheral blood cells
Rare EGFR mutations as oncogenic drivers
Decline in lung cancer mortality is almost exclusive to men
Related Articles
August 23, 2022
Pembrolizumab plus lenvatinib performs well in MPM
June 25, 2019
Systemic therapy of brain metastases
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com